サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1363166

分子診断の米国市場規模、シェア、動向分析レポート：疾患別、最終用途別、セグメント別予測、2023年～2030年

U.S. Molecular Diagnostics Market Size, Share & Trends Analysis Report By Disease (Healthcare-associated Infections, Respiratory), By End-use (Hospital Core Laboratory, Decentralized Test Sites), And Segment Forecasts, 2023 - 2030

出版日
ページ情報
英文 100 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.96円
分子診断の米国市場規模、シェア、動向分析レポート：疾患別、最終用途別、セグメント別予測、2023年～2030年
出版日: 2023年09月22日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

米国の分子診断市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、米国の分子診断市場規模は2023年から2030年にかけてCAGR 4.82％を記録し、2030年には84億6,000万米ドルに達すると予測されています。

市場成長の背景には、ウイルスや細菌の早期かつ迅速な検出など、分子診断検査を導入するメリットに対する認識が高まっていることがあります。さらに、確立されたヘルスケア部門と有利な償還政策に起因するアクセスの容易さが、予測期間中の市場成長を促進すると予想されます。

さらに、業界の有力企業は分子診断技術の技術的進歩に投資し、人的労力を削減し、即座に結果を出せるソリューションを開発しています。例えば、QIAGEN社は、診断ラボでの応用のためにEZ2 Connect MDxプラットフォームを発売しました。このプラットフォームは高度な自動化機能を備えており、24検体からRNAとDNAを30分のターンアラウンドタイムで精製します。

迅速検出アッセイの発展が市場の成長を支えるものと予想されます。これらの検査は、意思決定を迅速化し、分散型検査のターンアラウンドタイムを短縮することで、市場に革命をもたらしました。数多くの企業がアッセイや分子診断システムを開発しています。Qiagen社の淋菌・クラミジア・トラコマティス診断用Digene HC2 GC-ID DNA検査や、Danaher社（Cepheid社）のマクロライド耐性同定を伴うマイコプラズマ・ジェニタリウム診断用ResistancePlus MG FleXibleは、そのような製品の一例です。

Abbott社、Siemens Healthcare GmbH社、QIAGEN社、F. Hoffmann-La Roche Ltd社、Danaher社、Thermo Fisher Scientific, Inc社、Hologic Inc社、BD社などの市場の主要企業は、製品の浸透を強化し、顧客基盤を拡大するために様々な戦略を採用しています。例えば、2023年1月、サーモフィッシャーサイエンティフィックとアストラゼネカは、タグリッソの血液ベースおよび固形組織コンパニオン診断テストを開発するための提携を締結しました。

COVID-19のパンデミックは、コロナウイルスを検出できる迅速かつ新規の診断キットの開発を促進し、業界にプラスの影響を与えました。この結果、感染症分野で事業を展開する主要な市場参入企業の収益が増加しました。例えば、サーモフィッシャーサイエンティフィックは、2021年4月に診断キットに対する需要の高まりにより、150%の収益成長を報告しました。しかし、この地域ではワクチン接種の普及が進んでおり、予測期間中にCOVID-19検査の需要が減少すると予測されています。

米国の分子診断市場レポート・ハイライト

  • 疾患別では、呼吸器疾患分野が2022年の市場を独占しました。この成長は、呼吸器感染症の有病率の増加と、感染症の診断と治療のための診断検査が利用可能であることに関する意識の高まりに起因しています。
  • 最終用途別では、病院中核検査室が2022年に最大のシェアを占め、MRSA、黄色ブドウ球菌（SA）、エンテロウイルスなどの感染症の有病率の増加により、予測期間中に最も速いCAGRで成長すると予測されています。
  • 主要な業界プレーヤーは、新製品発売、提携、買収、事業拡大などさまざまな戦略を採用し、製品の浸透を強化し、より多くの消費者基盤を獲得しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国の分子診断市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 普及と成長の見通しマッピング
  • 業界のバリューチェーン分析
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因分析
  • 米国の分子診断市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析
    • 主要取引と戦略的提携の分析
    • 市場参入戦略

第4章 米国の分子診断市場：疾患別推定・動向分析

  • 市場規模、予測および動向分析、2018年から2030年まで

第5章 米国の分子診断市場：最終用途別推定・動向分析

  • 市場規模、予測および動向分析、2018年から2030年まで

第6章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 会社/競合の分類
  • ベンダー情勢
    • 主なディストリビューターとチャネルパートナーのリスト
    • 主な顧客
    • 主な市場シェア分析、2022年
    • Abbott
    • Siemens Healthcare GmbH
    • QIAGEN
    • F. Hoffmann-La Roche Ltd
    • Quest Diagnostics Incorporated
    • Danaher
    • Thermo Fisher Scientific, Inc.
    • Hologic Inc.
    • BD
    • Charles River Laboratories
    • Bio-Rad Laboratories, Inc.
    • Illumina, Inc.
    • Agilent Technologies, Inc.
図表

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 List of Secondary Sources
  • Table 3 U.S. Molecular Diagnostics Market, by Disease, 2018 - 2030 (USD Million)
  • Table 4 U.S. Molecular Diagnostics Market, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. molecular diagnostics market: market outlook
  • Fig. 9 U.S. Molecular Diagnostics Market Competitive Insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 U.S. molecular diagnostics market driver impact
  • Fig. 15 U.S. molecular diagnostics market restraint impact
  • Fig. 16 U.S. Molecular Diagnostics Market Strategic Initiatives Analysis
  • Fig. 17 U.S. molecular diagnostics market: disease movement analysis
  • Fig. 18 U.S. molecular diagnostics market: disease outlook and key takeaways
  • Fig. 19 Methicillin-Resistant Staphylococcus aureus market estimates and forecast, 2018 - 2030
  • Fig. 20 Staphylococcus aureus market estimates and forecast, 2018 - 2030
  • Fig. 21 Enterovirus market estimates and forecast, 2018 - 2030
  • Fig. 22 Clostridioides difficile market estimates and forecast, 2018 - 2030
  • Fig. 23 Van A market estimates and forecast, 2018 - 2030
  • Fig. 24 Sepsis Panel market estimates and forecast, 2018 - 2030
  • Fig. 25 Flu market estimates and forecast, 2018 - 2030
  • Fig. 26 Respiratory Syncytial Virus market estimates and forecast, 2018 - 2030
  • Fig. 27 Paraflu market estimates and forecast, 2018 - 2030
  • Fig. 28 Multidrug-Resistant Tuberculosis market estimates and forecast, 2018 - 2030
  • Fig. 29 Mycobacterium Avium-Intracellulare market estimates and forecast, 2018 - 2030
  • Fig. 30 Group A Streptococcal market estimates and forecast, 2018 - 2030
  • Fig. 31 Adenovirus market estimates and forecast, 2018 - 2030
  • Fig. 32 Human Metapneumovirus market estimates and forecast, 2018 - 2030
  • Fig. 33 Rhinoviruses market estimates and forecast, 2018 - 2030
  • Fig. 34 Middle East Respiratory Syndrome Coronavirus market estimates and forecast, 2018 - 2030
  • Fig. 35 Tuberculosis market estimates and forecast, 2018 - 2030
  • Fig. 36 Severe Acute Respiratory Syndrome Coronavirus 2 market estimates and forecast, 2018 - 2030
  • Fig. 37 Human Bocavirus-Infection market estimates and forecast, 2018 - 2030
  • Fig. 38 Bordetella market estimates and forecast, 2018 - 2030
  • Fig. 39 Mycoplasma Pneumonia market estimates and forecast, 2018 - 2030
  • Fig. 40 Respiratory Panels market estimates and forecast, 2018 - 2030
  • Fig. 41 Norovirus market estimates and forecast, 2018 - 2030
  • Fig. 42 Helicobacter pylori market estimates and forecast, 2018 - 2030
  • Fig. 43 Shiga toxin market estimates and forecast, 2018 - 2030
  • Fig. 44 GI Parasite Panel market estimates and forecast, 2018 - 2030
  • Fig. 45 GI Bacterial Panel market estimates and forecast, 2018 - 2030
  • Fig. 46 GI Viral Panel market estimates and forecast, 2018 - 2030
  • Fig. 47 GI Panels market estimates and forecast, 2018 - 2030
  • Fig. 48 Women's Health/STI market estimates and forecast, 2018 - 2030
  • Fig. 49 Chlamydia trachomatis (CT)/Neisseria gonorrhoeae (NG) market estimates and forecast, 2018 - 2030
  • Fig. 50 Trichomonas Vaginalis market estimates and forecast, 2018 - 2030
  • Fig. 51 Mycoplasma Genitalium market estimates and forecast, 2018 - 2030
  • Fig. 52 Human Papillomavirus market estimates and forecast, 2018 - 2030
  • Fig. 53 Bacterial Vaginosis market estimates and forecast, 2018 - 2030
  • Fig. 54 Gonorrhoea Colloquially market estimates and forecast, 2018 - 2030
  • Fig. 55 Mycoplasma Genitalium Resistance market estimates and forecast, 2018 - 2030
  • Fig. 56 Herpes Simplex Virus market estimates and forecast, 2018 - 2030
  • Fig. 57 Group B Streptococcus market estimates and forecast, 2018 - 2030
  • Fig. 58 Cytomegalovirus market estimates and forecast, 2018 - 2030
  • Fig. 59 Epstein-Barr virus market estimates and forecast, 2018 - 2030
  • Fig. 60 Varicella-Zoster Virus market estimates and forecast, 2018 - 2030
  • Fig. 61 BK virus market estimates and forecast, 2018 - 2030
  • Fig. 62 Human immunodeficiency viruses market estimates and forecast, 2018 - 2030
  • Fig. 63 Hepatitis C virus market estimates and forecast, 2018 - 2030
  • Fig. 64 Hepatitis B virus market estimates and forecast, 2018 - 2030
  • Fig. 65 Hepatitis E virus market estimates and forecast, 2018 - 2030
  • Fig. 66 Babesia market estimates and forecast, 2018 - 2030
  • Fig. 67 Zika market estimates and Forecast, 2018 - 2030
  • Fig. 68 West Nile Virus market estimates and forecast, 2018 - 2030
  • Fig. 69 Chikungunya virus/dengue virus market estimates and forecast, 2018 - 2030
  • Fig. 70 Enhancer of zest homolog 2 market estimates and forecast, 2018 - 2030
  • Fig. 71 PIK3CA market estimates and forecast, 2018 - 2030
  • Fig. 72 Malaria market estimates and forecast, 2018 - 2030
  • Fig. 73 Monkeypox Virus market estimates and forecast, 2018 - 2030
  • Fig. 74 Meningitis Panel market estimates and forecast, 2018 - 2030
  • Fig. 75 Lyme Panel market estimates and forecast, 2018 - 2030
  • Fig. 76 UTI Panel market estimates and forecast, 2018 - 2030
  • Fig. 77 Microsatellite Instability market estimates and forecast, 2018 - 2030
  • Fig. 78 B-raf market estimates and forecast, 2018 - 2030
  • Fig. 79 Epidermal Growth Factor Receptor market estimates and forecast, 2018 - 2030
  • Fig. 80 Kirsten rat sarcoma virus market estimates and forecast, 2018 - 2030
  • Fig. 81 Other market estimates and forecast, 2018 - 2030
  • Fig. 82 U.S. molecular diagnostics market: end-use movement analysis
  • Fig. 83 U.S. molecular diagnostics market: end-use outlook and key takeaways
  • Fig. 84 Hospital Core Laboratory market estimates and forecast, 2018 - 2030
  • Fig. 85 Hospital Alternative Sites market estimates and forecast, 2018 - 2030
  • Fig. 86 Decentralized Test Sites market estimates and forecast, 2018 - 2030
  • Fig. 87 Reference Lab market estimates and forecast, 2018 - 2030
  • Fig. 88 Participant categorization- U.S. molecular diagnostics market
  • Fig. 89 Market share of key market players- U.S. molecular diagnostics market
目次
Product Code: GVR-4-68040-126-4

U.S. Molecular Diagnostics Market Growth & Trends:

The U.S. molecular diagnostics market size is expected to reach USD 8.46 billion by 2030, registering a CAGR of 4.82% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The market growth is attributed to increasing awareness of the benefits of adopting molecular diagnostics tests, such as early and rapid detection of viruses and bacteria. Moreover, the ease of access owing to a well-established healthcare sector coupled with favorable reimbursement policies is anticipated to drive the market growth over the forecast period.

Moreover, prominent players in the industry are investing in the technological advancement of molecular diagnostics techniques to develop solutions capable of reducing human effort and delivering instant results. For instance, QIAGEN launched the EZ2 Connect MDx platform for its application in diagnostic laboratories. The platform is equipped with a high degree of automation to purify RNA & DNA from 24 samples with a turnaround time of 30 minutes.

Developments in rapid detection assays are anticipated to support the market growth. These tests have revolutionized the market by accelerating decision-making and reducing turnaround time for decentralized testing. Numerous players are developing assays and molecular diagnostic systems. Digene HC2 GC-ID DNA test for the diagnosis of Neisseria gonorrhea, & Chlamydia trachomatis by Qiagen and ResistancePlus MG FleXible for the diagnosis of Mycoplasma genitalium with macrolide-resistance identification by Danaher Corporation (Cepheid) are examples of such products.

Major players in the market such as Abbott, Siemens Healthcare GmbH, QIAGEN, F. Hoffmann-La Roche Ltd, Danaher, Thermo Fisher Scientific, Inc., Hologic Inc., and BD, are adopting various strategies to enhance their product penetration and expand their customer base. For instance, in January 2023, Thermo Fisher Scientific and AstraZeneca entered into a collaboration to develop a blood-based and solid tissue companion diagnostic test for Tagrisso.

The COVID-19 pandemic has positively impacted the industry by encouraging players to develop rapid and novel diagnostic kits capable of detecting coronavirus. This has resulted in positive revenue growth for major market players operating in the infectious disease segment. For instance, Thermo Fisher Scientific reported 150% revenue growth owing to the rising demand for diagnostics offerings in April 2021. However, the rising adoption of vaccination in the region is anticipated to reduce the demand for COVID-19 testing over the forecast period.

U.S. Molecular Diagnostics Market Report Highlights:

  • Based on disease, the respiratory disease segment dominated the market in 2022. The growth is attributed to the increasing prevalence of respiratory infections coupled with the increasing awareness regarding the availability of diagnostic tests for diagnosing and treating infections
  • Based on end-use, the hospital core laboratory held the largest share in 2022 and is anticipated to grow at the fastest CAGR over the forecast period owing to the increasing prevalence of infections, such as MRSA, Staphylococcus aureus (SA), and enterovirus
  • Major industry players adopt different strategies such as new product launches, collaborations, acquisitions, and expansions to enhance their product penetration and gain a larger consumer base

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Disease
    • 1.1.2. End-use
    • 1.1.3. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
    • 1.6.2. Volume price analysis (Model 2)
      • 1.6.2.1. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Disease outlook
    • 2.2.2. End-use outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Molecular Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Industry Value Chain Analysis
  • 3.4. Market Dynamics
    • 3.4.1. Market Driver Analysis
      • 3.4.1.1. Increase in geriatric population
      • 3.4.1.2. Introduction of technologically advanced products
      • 3.4.1.3. Increase in demand for point-of-care testing
      • 3.4.1.4. Growing prevalence of target diseases
      • 3.4.1.5. Increasing external funding for R&D
    • 3.4.2. Market Restraint Analysis
      • 3.4.2.1. Presence of Ambiguous Regulatory Framework
      • 3.4.2.2. High prices of molecular diagnostics tests
  • 3.5. U.S. Molecular Diagnostics Market Analysis Tools
    • 3.5.1. Industry Analysis - Porter's
      • 3.5.1.1. Supplier power
      • 3.5.1.2. Buyer power
      • 3.5.1.3. Substitution threat
      • 3.5.1.4. Threat of new entrant
      • 3.5.1.5. Competitive rivalry
    • 3.5.2. PESTEL Analysis
      • 3.5.2.1. Political landscape
      • 3.5.2.2. Technological landscape
      • 3.5.2.3. Economic Landscape
    • 3.5.3. Major Deals & Strategic Alliances Analysis
    • 3.5.4. Market Entry Strategies

Chapter 4. U.S. Molecular Diagnostics Market: Disease Estimates & Trend Analysis

  • 4.1. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.1.1. Healthcare-Associated Infections
      • 4.1.1.1. Methicillin-Resistant Staphylococcus aureus
      • 4.1.1.1.1. Methicillin-Resistant Staphylococcus aureus Market Estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.1.2. Staphylococcus aureus
      • 4.1.1.2.1. Staphylococcus aureus Market Estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.1.3. Enterovirus
      • 4.1.1.3.1. Enterovirus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.1.4. Clostridioides difficile
      • 4.1.1.4.1. Clostridioides difficile market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.1.5. Van A
      • 4.1.1.5.1. Van A market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.1.6. Sepsis Panel
      • 4.1.1.6.1. Sepsis Panel market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.2. Respiratory
      • 4.1.2.1. Flu
      • 4.1.2.1.1. Flu market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.2. Respiratory Syncytial Virus
      • 4.1.2.2.1. Respiratory Syncytial Virus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.3. Paraflu
      • 4.1.2.3.1. Paraflu market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.4. Multidrug-Resistant Tuberculosis
      • 4.1.2.4.1. Multidrug-Resistant Tuberculosis market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.5. Mycobacterium Avium-Intracellular
      • 4.1.2.5.1. Mycobacterium Avium-Intracellulare market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.6. Group A Streptococcal
      • 4.1.2.6.1. Group A Streptococcal market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.7. Adenovirus
      • 4.1.2.7.1. Adenovirus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.8. Human Metapneumovirus
      • 4.1.2.8.1. Human Metapneumovirus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.9. Rhinoviruses
      • 4.1.2.9.1. Rhinoviruses market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.10. Middle East Respiratory Syndrome Coronavirus
      • 4.1.2.10.1. Middle East Respiratory Syndrome Coronavirus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.11. Tuberculosis
      • 4.1.2.11.1. Tuberculosis market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.12. Severe Acute Respiratory Syndrome Coronavirus 2
      • 4.1.2.12.1. Severe Acute Respiratory Syndrome Coronavirus 2 market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.13. Human Bocavirus-Infection
      • 4.1.2.13.1. Human Bocavirus-Infection market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.14. Bordetella
      • 4.1.2.14.1. Bordetella market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.15. Mycoplasma Pneumonia
      • 4.1.2.15.1. Mycoplasma Pneumonia market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.16. Respiratory Panels
      • 4.1.2.16.1. Respiratory Panels market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.3. Gastrointestinal
      • 4.1.3.1. Norovirus
      • 4.1.3.1.1. Norovirus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.3.2. Helicobacter pylori
      • 4.1.3.2.1. Helicobacter pylori market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.3.3. Shiga toxin
      • 4.1.3.3.1. Shiga toxin Market Estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.3.4. GI Parasite Panel
      • 4.1.3.4.1. GI Parasite Panel market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.3.5. GI Bacterial Panel
      • 4.1.3.5.1. GI Bacterial Panel market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.3.6. GI Viral Panel
      • 4.1.3.6.1. GI Viral Panel market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.3.7. GI Panels
      • 4.1.3.7.1. GI Panels market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.4. Women's Health/STI
      • 4.1.4.1. Chlamydia trachomatis (CT)/Neisseria gonorrhoeae (NG)
      • 4.1.4.1.1. Chlamydia trachomatis (CT)/Neisseria gonorrhoeae (NG) market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.4.2. Trichomonas Vaginalis
      • 4.1.4.2.1. Trichomonas Vaginalis market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.4.3. Mycoplasma Genitalium
      • 4.1.4.3.1. Mycoplasma genitalium market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.4.4. Human Papillomavirus
      • 4.1.4.4.1. Human Papillomavirus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.4.5. Bacterial Vaginosis
      • 4.1.4.5.1. Bacterial Vaginosis market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.4.6. Gonorrhoea Colloquially
      • 4.1.4.6.1. Gonorrhoea Colloquially market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.4.7. Mycoplasma Genitalium Resistance
      • 4.1.4.7.1. Mycoplasma Genitalium Resistance market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.4.8. Herpes Simplex Virus
      • 4.1.4.8.1. Herpes Simplex Virus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.4.9. Group B Streptococcus
      • 4.1.4.9.1. Group B Streptococcus market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.5. Immunocompromised
      • 4.1.5.1. Cytomegalovirus
      • 4.1.5.1.1. Cytomegalovirus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.5.2. Epstein-Barr virus
      • 4.1.5.2.1. Epstein-Barr virus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.5.3. Varicella-Zoster Virus
      • 4.1.5.3.1. Varicella-Zoster Virus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.5.4. BK virus
      • 4.1.5.4.1. BK virus market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.6. Virology
      • 4.1.6.1. Human immunodeficiency viruses
      • 4.1.6.1.1. Human immunodeficiency viruses market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.6.2. Hepatitis C virus
      • 4.1.6.2.1. Hepatitis C virus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.6.3. Hepatitis B virus
      • 4.1.6.3.1. Hepatitis B virus Market Estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.6.4. Hepatitis E virus
      • 4.1.6.4.1. Hepatitis E virus market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.7. Other Targets
      • 4.1.7.1. Babesia
      • 4.1.7.1.1. Babesia market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.7.2. Zika
      • 4.1.7.2.1. Zika market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.7.3. West Nile Virus
      • 4.1.7.3.1. West Nile Virus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.7.4. Chikungunya virus/Dengue virus
      • 4.1.7.4.1. Chikungunya virus/Dengue Virus Market Estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.7.5. Enhancer of zeste homolog 2
      • 4.1.7.5.1. Enhancer of zeste homolog 2 market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.7.6. PIK3CA
      • 4.1.7.6.1. PIK3CA market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.7.7. Malaria
      • 4.1.7.7.1. Malaria market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.7.8. Monkeypox Virus
      • 4.1.7.8.1. Monkeypox Virus market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.8. Other Panels
      • 4.1.8.1. Meningitis Panel
      • 4.1.8.1.1. Meningitis Panel market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.8.2. Lyme Panel
      • 4.1.8.2.1. Lyme Panel market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.8.3. UTI Panel
      • 4.1.8.3.1. UTI Panel market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.9. Oncology
      • 4.1.9.1. Microsatellite Instability
      • 4.1.9.1.1. Microsatellite Instability market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.9.2. B-raf
      • 4.1.9.2.1. B-raf market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.9.3. Epidermal Growth Factor Receptor
      • 4.1.9.3.1. Epidermal Growth Factor Receptor market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.9.4. Kirsten Rat Sarcoma Virus
      • 4.1.9.4.1. Kirsten Rat Sarcoma Virus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.9.5. Others
      • 4.1.9.5.1. Others Market Estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. U.S. Molecular Diagnostics Market: End-use Estimates & Trend Analysis

  • 5.1. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.1.1. Hospital Core Laboratory
      • 5.1.1.1. Hospital Core Laboratory market estimates and forecast 2018 to 2030 (USD Million)
    • 5.1.2. Hospital Alternative Sites
      • 5.1.2.1. Hospital Alternative Sites market estimates and forecast 2018 to 2030 (USD Million)
    • 5.1.3. Decentralized Test Sites
      • 5.1.3.1. Decentralized Test Site market estimates and forecast 2018 to 2030 (USD Million)
    • 5.1.4. Reference Lab
      • 5.1.4.1. Reference Lab market Estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Company/Competition Categorization
  • 6.3. Vendor Landscape
    • 6.3.1. List of key distributors and channel partners
    • 6.3.2. Key customers
    • 6.3.3. Key Company Market Share Analysis, 2022
    • 6.3.4. Abbott
      • 6.3.4.1. Company overview
      • 6.3.4.2. Financial performance
      • 6.3.4.3. Product benchmarking
      • 6.3.4.4. Strategic initiatives
    • 6.3.5. Siemens Healthcare GmbH
      • 6.3.5.1. Company overview
      • 6.3.5.2. Financial performance
      • 6.3.5.3. Product benchmarking
      • 6.3.5.4. Strategic initiatives
    • 6.3.6. QIAGEN
      • 6.3.6.1. Company overview
      • 6.3.6.2. Financial performance
      • 6.3.6.3. Product benchmarking
      • 6.3.6.4. Strategic initiatives
    • 6.3.7. F. Hoffmann-La Roche Ltd
      • 6.3.7.1. Company overview
      • 6.3.7.2. Financial performance
      • 6.3.7.3. Product benchmarking
      • 6.3.7.4. Strategic initiatives
    • 6.3.8. Quest Diagnostics Incorporated
      • 6.3.8.1. Company overview
      • 6.3.8.2. Financial performance
      • 6.3.8.3. Product benchmarking
      • 6.3.8.4. Strategic initiatives
    • 6.3.9. Danaher
      • 6.3.9.1. Company overview
      • 6.3.9.2. Financial performance
      • 6.3.9.3. Product benchmarking
      • 6.3.9.4. Strategic initiatives
    • 6.3.10. Thermo Fisher Scientific, Inc.
      • 6.3.10.1. Company overview
      • 6.3.10.2. Financial performance
      • 6.3.10.3. Product benchmarking
      • 6.3.10.4. Strategic initiatives
    • 6.3.11. Hologic Inc.
      • 6.3.11.1. Company overview
      • 6.3.11.2. Financial performance
      • 6.3.11.3. Product benchmarking
      • 6.3.11.4. Strategic initiatives
    • 6.3.12. BD
      • 6.3.12.1. Company overview
      • 6.3.12.2. Financial performance
      • 6.3.12.3. Product benchmarking
      • 6.3.12.4. Strategic initiatives
    • 6.3.13. Charles River Laboratories
      • 6.3.13.1. Company overview
      • 6.3.13.2. Financial performance
      • 6.3.13.3. Product benchmarking
      • 6.3.13.4. Strategic initiatives
    • 6.3.14. Bio-Rad Laboratories, Inc.
      • 6.3.14.1. Company overview
      • 6.3.14.2. Financial performance
      • 6.3.14.3. Product benchmarking
      • 6.3.14.4. Strategic initiatives
    • 6.3.15. Illumina, Inc.
      • 6.3.15.1. Company Overview
      • 6.3.15.2. Financial performance
      • 6.3.15.3. Product benchmarking
      • 6.3.15.4. Strategic initiatives
    • 6.3.16. Agilent Technologies, Inc.
      • 6.3.16.1. Company Overview
      • 6.3.16.2. Financial performance
      • 6.3.16.3. Product benchmarking
      • 6.3.16.4. Strategic initiatives